scispace - formally typeset
Journal ArticleDOI

Anti-cancer drugs

Elke S. Bergmann-Leitner
- 31 Mar 2005 - 
- Vol. 14, Iss: 11, pp 1048-1048
Reads0
Chats0
About
This article is published in Current Pharmaceutical Design.The article was published on 2005-03-31. It has received 882 citations till now. The article focuses on the topics: Introductory Journal Article.

read more

Citations
More filters
Journal ArticleDOI

The status of platinum anticancer drugs in the clinic and in clinical trials.

TL;DR: The status of platinum anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued during clinical trials are updated, and the results in the context of where the field will develop over the next decade are discussed.
Journal ArticleDOI

Natural products to drugs: natural product derived compounds in clinical trials

TL;DR: Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural products for which clinical trials have been halted or discontinued since 2005.
Journal ArticleDOI

Cellular distribution and functions of P2 receptor subtypes in different systems.

TL;DR: This review is aimed at providing readers with a comprehensive reference article about the distribution and function of P2 receptors in all the organs, tissues, and cells in the body.
Journal ArticleDOI

Natural products: an evolving role in future drug discovery.

TL;DR: The present review describes natural products, semi-synthetic NPs and NP-derived compounds that have undergone clinical evaluation or registration from 2005 to 2010 by disease area i.e. infectious, immunological, cardiovascular, neurological, inflammatory and related diseases and oncology.
References
More filters
Journal ArticleDOI

Generation of reactive oxygen species by a persulfide (BnSSH)

TL;DR: Experiments with synthetic benzyl hydrodisulfide (BnSSH) provide direct evidence that persulfides readily decompose to produce reactive oxygen species under physiologically relevant conditions.
Journal ArticleDOI

Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: A beneficial strategy to combat non-small cell lung cancer

TL;DR: It is shown that H1299 cells display a considerably lower sensitivity to erlotinib treatment, which can be restored by combining erlot inib with rapamycin or with imatinib, though to a lesser extent.
Journal ArticleDOI

Combined histone deacetylase and NF-κB inhibition sensitizes non-small cell lung cancer to cell death

TL;DR: Combined HDI and NF-kappaB inhibition using BAY-11-7085 sensitizes NSCLC cells to cell death and appears promising as a novel treatment strategy for this disease.
Journal ArticleDOI

Binding of curcumin and its long chain derivatives to the activator binding domain of novel protein kinase C.

TL;DR: The present result shows that curcumin and its long chain derivatives bind to the C1B subdomain of novel PKCs and can be further modified structurally to improve its binding and activity.